Lung Cancers With Coral Olazagasti, MD

Oncology / Hematology

Dr. Coral Olazagasti is a medical oncologist and Assistant Professor at the Sylvester Comprehensive Cancer Center, University of Miami. She specializes in head and neck as well as thoracic malignancies. Dr. Olazagasti earned her medical degree from the Universidad Central del Caribe in Bayamón, Puerto Rico.

Coral Olazagasti, MD
Oncology / Hematology

DeLLphi 301 is a Game-Changer in NSCLC Research: Learn More From ASCO 2025 - 15 day(s) ago

Dear readers, After the promising results of IMforte, what better time to spotlight another game-changer in small cell lung cancer (SCLC): the DeLLphi 301 trial.…

Coral Olazagasti, MD
Oncology / Hematology

IMforte Trial Delivers Long-Awaited Breakthrough in Maintenance Therapy - 15 day(s) ago

Dear readers, At this year’s ASCO Annual Meeting, the IMforte trial delivered what the small cell lung cancer (SCLC) community has long awaited: a breakthrough in maintenance therapy.…

Coral Olazagasti, MD
Oncology / Hematology

TROPION-Lung 2 Study Reviews First-Line Treatment in Advanced NSCLC at ASCO 2025 - 18 day(s) ago

Dear readers, The TROPION-Lung 2 study, a Phase 1b trial, explored the combination of Dato-DXd plus pembrolizumab (with or without platinum therapy) as a first-line…

Coral Olazagasti, MD
Oncology / Hematology

NSCLC at ASCO 2025: HERTHENA Lung 2 Shows Improved PFS - 18 day(s) ago

Dear readers, In the recently presented study, HERTHENA lung 2, investigators compared the use of Her 3-DXd in EGFR-mutant non-small cell lung cancer (NSCLC) after…